
XTL Biopharmaceuticals Ltd. XTLB
€ 0.50
-2.0%
Geschäftsbericht 2024
hinzugefügt 21.03.2026
XTL Biopharmaceuticals Ltd. Current Ratio 2011-2026 | XTLB
Current Ratio Jährlich XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.46 | - | - | - | 25.6 | 31.1 | 33.9 | 2.22 | 8.35 | 9.78 | 3.24 | 4.17 | 2.3 | 2.52 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 33.9 | 1.46 | 11.3 |
Current Ratio anderer Aktien in der Pharmaeinzelhändler
| Name | Current Ratio | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M | ||
|
Amgen
AMGN
|
1.44 | $ 350.54 | 0.79 % | $ 189 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.94 | $ 19.39 | -0.56 % | $ 906 M | ||
|
Altimmune
ALT
|
5.09 | $ 3.45 | 3.14 % | $ 304 M | ||
|
Autolus Therapeutics plc
AUTL
|
2.2 | $ 1.4 | 1.82 % | $ 357 M | ||
|
I-Mab
IMAB
|
8.96 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B | ||
|
Aytu BioScience
AYTU
|
1.47 | $ 2.62 | 0.21 % | $ 16.5 M | ||
|
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
0.889 | $ 219.22 | -1.2 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | ||
|
Benitec Biopharma
BNTC
|
43.4 | $ 11.01 | 0.27 % | $ 453 M | ||
|
ARCA biopharma
ABIO
|
28.7 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
1.6 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.81 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
2.39 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
7.98 | - | 10.36 % | $ 9.8 M | ||
|
Compugen Ltd.
CGEN
|
7.46 | $ 2.12 | 1.44 % | $ 198 M | ||
|
Acasti Pharma
ACST
|
13.4 | - | 4.01 % | $ 150 M | ||
|
Coherus BioSciences
CHRS
|
1.31 | $ 1.58 | 3.95 % | $ 185 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
3.27 | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
0.41 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | ||
|
Cellectis S.A.
CLLS
|
1.31 | $ 3.39 | 1.5 % | $ 116 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
3.57 | $ 0.6 | -1.79 % | $ 6.87 M | ||
|
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
11.3 | $ 12.85 | 0.86 % | $ 774 M | ||
|
Atreca
BCEL
|
2.02 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
2.37 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
4.13 | - | -10.95 % | $ 876 K | ||
|
CorMedix
CRMD
|
1.96 | $ 6.43 | 2.88 % | $ 463 K | ||
|
Cara Therapeutics
CARA
|
1.83 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.05 | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.47 | - | -74.18 % | $ 955 K | ||
|
CytomX Therapeutics
CTMX
|
2.88 | $ 4.41 | -1.01 % | $ 608 M | ||
|
Checkpoint Therapeutics
CKPT
|
0.372 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
0.629 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
9.51 | $ 21.1 | 4.59 % | $ 3.47 B | ||
|
Dyadic International
DYAI
|
3.51 | $ 0.9 | -4.79 % | $ 25.9 M | ||
|
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
3.76 | $ 4.29 | 1.06 % | $ 712 M |